for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Second Sight Medical Products Inc

EYES.PH

Latest Trade

5.98USD

Change

-0.34(-5.38%)

Volume

8,928

Today's Range

5.93

 - 

6.27

52 Week Range

0.73

 - 

20.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.32
Open
6.20
Volume
8,928
3M AVG Volume
503.10
Today's High
6.27
Today's Low
5.93
52 Week High
20.00
52 Week Low
0.73
Shares Out (MIL)
27.91
Market Cap (MIL)
176.11
Forward P/E
--
Dividend (Yield %)
--

Next Event

Second Sight Medical Products Inc Annual Shareholders Meeting

Latest Developments

More

Second Sight Medical Files Prospectus Relates To Offer, Sale From Time To Time By Selling Shareholders Up To 4.65 Mln Shares Of Co's Common Stock

Second Sight Medical Products Inc Says Matthew Pfeffer Stepped Down As Acting CEO

Second Sight Medical Products Receives FDA Approval For The Argus 2S Retinal Prosthesis System

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Second Sight Medical Products Inc

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.

Industry

Medical Equipment & Supplies

Contact Info

12744 San Fernando Rd Bldg 3

SYLMAR, CA

91342-3853

United States

+1.818.8335000

http://www.secondsight.com/

Executive Leadership

Gregg G. Williams

Chairman of the Board

Scott Dunbar

Acting Chief Executive Officer

Ted Randolph

Vice President - Operations

Edward David Randolph

Vice President - Manufacturing

Stephen D. Okland

Chief Commercial Officer

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-331.85
Return on Equity (TTM)
-141.32

Latest News

Latest News

BRIEF-Second Sight Medical Products On July 7 Entered Into Lease With Sylmar Biomedical Park To Lease Smaller Portion Of Present Facility

* SECOND SIGHT MEDICAL PRODUCTS - ON JULY 7 ENTERED INTO LEASE WITH SYLMAR BIOMEDICAL PARK, LLC, TO LEASE SMALLER PORTION OF PRESENT FACILITY

BRIEF-Second Sight Says Ga Global Partners Conducted Auction Of Co's Equipment, Furniture, Surplus Assets

* SECOND SIGHT MEDICAL PRODUCTS - ON JUNE 25, 2020, GA GLOBAL PARTNERS CONDUCTED AUCTION OF CO'S OFFICE EQUIPMENT, FURNITURE, OTHER SURPLUS ASSETS

BRIEF-GA Global Partners Will Conduct Online Public Auction Of Assets Of Second Sight Medical Products

* GA GLOBAL PARTNERS - WILL CONDUCT ONLINE PUBLIC AUCTION OF ASSETS OF SECOND SIGHT MEDICAL PRODUCTS ON JUNE 25 Source text for Eikon: Further company coverage:

BRIEF-Empery Asset Management Lp Reports 9.51% Passive Stake In Second Sight Medical Products As Of May 1

* EMPERY ASSET MANAGEMENT LP REPORTS 9.51% PASSIVE STAKE IN SECOND SIGHT MEDICAL PRODUCTS AS OF MAY 1 - SEC FILING Source text - https://bit.ly/3b44BKc Further company coverage:

BRIEF-Sabby Management Llc Reports 9.50% Passive Stake In Second Sight Medical Products As Of May 1

* SABBY MANAGEMENT LLC REPORTS 9.50% PASSIVE STAKE IN SECOND SIGHT MEDICAL PRODUCTS AS OF MAY 1 - SEC FILING Source text - https://bit.ly/3d6TEJ7 Further company coverage:

BRIEF-Second Sight Medical Products Says Public Offering Of 7.50 Mln Common Shares Priced At $1.00 Per Share

* SECOND SIGHT MEDICAL PRODUCTS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Second Sight Medical Products Provides Business Update

* SECOND SIGHT MEDICAL PRODUCTS - HAS TAKEN STEPS TO REDUCE OVERHEAD AND CONSERVE LIQUIDITY AS IT CONTINUES OPERATIONS WHILE ASSESSING STRATEGIC OPTIONS Source text for Eikon: Further company coverage:

BRIEF-Second Sight Medical Products On April 17, Laid Off 15 Employees Including Patrick Ryan, COO

* SECOND SIGHT MEDICAL PRODUCTS INC - ON APRIL 17, LAID OFF 15 EMPLOYEES INCLUDING PATRICK RYAN, CHIEF OPERATING OFFICER

BRIEF-Second Sight Announces Employee Layoffs, Intent To Wind Down Operations And Appointment Of Matthew Pfeffer As Acting CEO

* SECOND SIGHT ANNOUNCES EMPLOYEE LAYOFFS, INTENT TO WIND DOWN OPERATIONS AND APPOINTMENT OF MATTHEW PFEFFER AS ACTING CEO

BRIEF-Second Sight Q4 Loss Per Share $0.50

* SECOND SIGHT REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Second Sight Names Gregg Williams As Acting CEO

* SECOND SIGHT ANNOUNCES DEPARTURE OF WILL MCGUIRE, PRESIDENT AND CEO, AND APPOINTMENT OF GREGG WILLIAMS AS ACTING CEO

BRIEF-Second Sight Reports Q1 Loss Per Share $0.17

* Q1 NON-GAAP LOSS PER SHARE $0.14 EXCLUDING ITEMS Source text for Eikon: Further company coverage:

BRIEF-Second Sight Completes $10 Mln Private Placement Of Common Stock With Chairman Of Board Of Directors

* SECOND SIGHT COMPLETES $10 MILLION PRIVATE PLACEMENT OF COMMON STOCK WITH GREGG WILLIAMS, CHAIRMAN OF THE BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up